CARTITUDE-1 FOLLOW-UP ANALYSIS
5-Year Baseline Characteristics
5-year follow-up
CARTITUDE-1 study1
You are now viewing an analysis from the CARTITUDE-1 trial with a median duration of follow-up of 61.3 months.
This information is not included in the current USPI and should be interpreted with caution.
This information is not included in the current USPI and should be interpreted with caution.
This post hoc analysis was conducted ≥5 years (61.3-month median follow-up) after infusion to provide further insights into long-term
clinical benefits associated with CARVYKTI®.
Baseline characteristics:
All Infused patients (N=97)
97% daratumumab-refractory
(n=94/97)
25.3% with high-risk* cytogenetics
(n=23/91)
13.4% with extramedullary plasmacytomas
(n=13/97)
87.6% triple-class refractory (n=85/97)
≥5 yrs alive and progression-free (n=32)
PD within 5 years (n=46)
Previous LoT, median (range)
6.5 (3-14)
5.0 (3-18)
High-risk* cytogenetics, No./n (%)
7/30 (23.3)†
12/45 (26.7)
Extramedullary plasmacytomas, No. (%)
4 (12.5)‡
6 (13.0)
≥5 yrs alive and
progression-free (n=32)
progression-free (n=32)
Previous LoT, median (range)
6.5 (3-14)
High-risk* cytogenetics,
No./n (%)
No./n (%)
7/30 (23.3)†
Extramedullary plasmacytomas,
No. (%)
No. (%)
4 (12.5)‡
PD within 5 years (n=46)
Previous LoT, median (range)
5.0 (3-18)
High-risk* cytogenetics,
No./n (%)
No./n (%)
12/45 (26.7)
Extramedullary plasmacytomas,
No. (%)
No. (%)
6 (13.0)
LoT=line(s) of therapy; PD=progressive disease;
USPI=US Prescribing Information.
*Either del17p, t(14;16), or t(4;14).
†4 patients had del17p, 2 had t(14;16), and 1 had
del17p and t(14;16).
‡Extramedullary disease denotes soft tissue
plasmacytoma not contiguous with bone.
36% of RESPONDERS CONTINUED to respond at 60 months
You are now viewing an analysis from the CARTITUDE-1 trial with a median duration of follow-up of 61.3 months.
This information is not included in the current USPI and should be interpreted with caution.
This information is not included in the current USPI and should be interpreted with caution.
Duration of response in CARVYKTI®
responders (n=94)1-3*†
• At data cut-off (median follow-up of 61.3 months), 46% of patients (45/97) were alive and in long-term follow-up
CI=confidence interval; DOR=duration of response; USPI=US Prescribing Information.
Percentages rounded to nearest whole number.
*Responders defined as having partial response or better as determined by investigator.3
†Median follow-up was 61.3 months in the All Treated Analysis Set. Response and disease progression assessed by investigator.
Learn More About CARVYKTI®